adcomm split vote short
What it checks
When a drug's FDA review keeps getting delayed (3+ different target dates), we short the sponsor for the next 1-2 months.
Mechanism
Contested FDA AdComm reviews (split votes, e.g. 7-6) predict final-PDUFA rejection more often than baseline; sponsor stock drifts negative 30-60d before action date.
Signal rule
Drug crosses >=3 distinct PDUFA action-date revisions in fda_adcomm (contested-review proxy) -> SHORT sponsor T+1; hold 30/60 trading days.
Data dependencies
daily_pricesAdjusted-close OHLCV for every US-listed ticker; primary price feed.
fda_adcommWorker data table — see services/worker schema.
Expected edge
- Paper alpha
- above-baseline rejection
- Paper window
- T+1 to T+60d
Carpenter et al 2010: above-baseline rejection rate on contested reviews.
Example tickers where this is likely to fire
Illustrative only — the signal fires based on the live data, not a fixed list.
Related families
pdufa extension shortEvent / FDAFDA PDUFA action-letter delay (Complete Response Letter or 3-month extension) signals additional analyses/trials are required; sponsor stock reprices -3 to -5% event-day with -2% drift over 30d.
fda adcomm pdufaEventFDA adcomm + PDUFA target-action dates are ±15% binaries.
Explore adcomm split vote short on alphactor.ai
See which tickers this family is currently firing on, with live signals and rankings.